Controversy between Obesity andComplications in Thromboembolic Disease,Series of Cases of Fuenlabrada UniversityHospital in Tinzaparine Treatment

Thromboembolic disease is the second leading cause of death in cancer patients (mostly, in the first year from diagnosis). The needing for anticoagulation with low molecular weight heparin (LMWH) in patients who are at high risk for complications (risk of bleeding in digestive tumors, brain tumors ...) require us to be more aware of their evolution. In addition, presenting venous thromboembolic disease (VTE) is usually an exclusion criterion in clinical trials so we do not know what happens with the combination of new drugs. Our objective is to study in a sample of 31 patients diagnosed with VTE, whether incidence of complications such as re-thrombosis or bleeding is higher in patients treated with tinzaparin (LMWH) depending on BMI.